Circulating proteins as predictive and prognostic biomarkers in breast cancer

Veyssière, Hugo; Bidet, Yannick; Penault‐Llorca, Frédérique; Radosevic‐Robin, Nina; Durando, Xavier

doi:10.1186/s12014-022-09362-0

Cited by 37 publications

(30 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is hoped that in the future the biomarker research in youth with neurodevelopmental disorders will benefit from larger sam ples, consistent methods, concerted efforts focusing on replica tion, building on recent consortia and other promising ongoing efforts 82,83 . This research should follow the lead of biomarker research in adults with severe mental disorders 84,85 and of other areas of medicine 86,87 , that can inform appropriate assessment techniques. Future research should focus on machine learning and other advanced data analytic techniques as well as multivar iable and multilevel biomarker approaches that may arguably be best suited to match the complexities of mental disorders.…”

Section: Discussionmentioning

confidence: 99%

Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review

et al. 2023

View full text Add to dashboard Cite

Neurodevelopmental disorders – including attention‐deficit/hyperactivity disorder (ADHD), autism spectrum disorder, communication disorders, intellectual disability, motor disorders, specific learning disorders, and tic disorders – manifest themselves early in development. Valid, reliable and broadly usable biomarkers supporting a timely diagnosis of these disorders would be highly relevant from a clinical and public health standpoint. We conducted the first systematic review of studies on candidate diagnostic biomarkers for these disorders in children and adolescents. We searched Medline and Embase + Embase Classic with terms relating to biomarkers until April 6, 2022, and conducted additional targeted searches for genome‐wide association studies (GWAS) and neuroimaging or neurophysiological studies carried out by international consortia. We considered a candidate biomarker as promising if it was reported in at least two independent studies providing evidence of sensitivity and specificity of at least 80%. After screening 10,625 references, we retained 780 studies (374 biochemical, 203 neuroimaging, 133 neurophysiological and 65 neuropsychological studies, and five GWAS), including a total of approximately 120,000 cases and 176,000 controls. While the majority of the studies focused simply on associations, we could not find any biomarker for which there was evidence – from two or more studies from independent research groups, with results going into the same direction – of specificity and sensitivity of at least 80%. Other important metrics to assess the validity of a candidate biomarker, such as positive predictive value and negative predictive value, were infrequently reported. Limitations of the currently available studies include mostly small sample size, heterogeneous approaches and candidate biomarker targets, undue focus on single instead of joint biomarker signatures, and incomplete accounting for potential confounding factors. Future multivariable and multi‐level approaches may be best suited to find valid candidate biomarkers, which will then need to be validated in external, independent samples and then, importantly, tested in terms of feasibility and cost‐effectiveness, before they can be implemented in daily clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Several circulating proteins have been identified in the plasma and serum of patients with breast cancer [ 19 ] but we still lack highly sensitive and specific biomarkers. Below, we discuss some of the pertinent proteins that were significantly altered among the different groups (B/N, M/M and M/B) in our analysis of saliva and/or serum and their relevance for a potential biomarkers for breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Potential Early Markers for Breast Cancer: A Proteomic Approach Comparing Saliva and Serum Samples in a Pilot Study

Sinha

Fogle

Gulfidan

et al. 2023

IJMS

View full text Add to dashboard Cite

Breast cancer is the second leading cause of death for women in the United States, and early detection could offer patients the opportunity to receive early intervention. The current methods of diagnosis rely on mammograms and have relatively high rates of false positivity, causing anxiety in patients. We sought to identify protein markers in saliva and serum for early detection of breast cancer. A rigorous analysis was performed for individual saliva and serum samples from women without breast disease, and women diagnosed with benign or malignant breast disease, using isobaric tags for relative and absolute quantitation (iTRAQ) technique, and employing a random effects model. A total of 591 and 371 proteins were identified in saliva and serum samples from the same individuals, respectively. The differentially expressed proteins were mainly involved in exocytosis, secretion, immune response, neutrophil-mediated immunity and cytokine-mediated signaling pathway. Using a network biology approach, significantly expressed proteins in both biological fluids were evaluated for protein–protein interaction networks and further analyzed for these being potential biomarkers in breast cancer diagnosis and prognosis. Our systems approach illustrates a feasible platform for investigating the responsive proteomic profile in benign and malignant breast disease using saliva and serum from the same women.

show abstract

“…For example, an increase in hepatocyte growth factors was shown in studies to be correlated with breast cancers as a risk factor and a high risk in metastatic progression [ 28 ]. However, interestingly, an increase in hepatocyte growth factors was paradoxically associated with long relapse-free survival [ 29 ]. In a systematic review and meta-analysis, circulating tumor DNA (ctDNA) was associated with a high risk of relapse; however, the review mentions there was heterogeneity of the studies, that all studies could not be included since relevant data were not available, and the studies used different techniques to quantify ctDNA [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort

Prieur¹,

Harper

Khan

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Background Recurrence and metastases are still frequent outcomes after initial tumour control in women diagnosed with breast cancer. Although therapies are selected based on tumour characteristics measured at baseline, prognostic biomarkers can identify those at risk of poor outcomes. Circulating progastrin or hPG80 was found to be associated with survival outcomes in renal and hepatocellular carcinomas and was a plausible prognostic biomarker for breast cancer. Methods Women with incident breast cancers from Calgary, Alberta, Canada enrolled in the Breast to Bone (B2B) study between 2010 to 2016 and provided blood samples prior to any treatment initiation. Plasma from these baseline samples were analysed for circulating progastrin or hPG80. Participant characteristics as well as tumour ones were evaluated for their association with hPG80 and survival outcomes (time to recurrence, recurrence – free survival, breast cancer specific survival and overall survival) in Cox proportional hazards regression models. Results The 464 participants with measurable hPG80 in this study had an average age of 57.03 years (standard deviation of 11.17 years) and were predominantly diagnosed with Stage I (52.2%) and Stage II (40.1%) disease. A total of 50 recurrences and 50 deaths were recorded as of June 2022. In Cox PH regression models adjusted for chemotherapy, radiation therapy, cancer stage and age at diagnosis, log hPG80 (pmol/L) significantly increased the risks for recurrence (Hazard Ratio (HR) = 1.330, 95% Confidence Interval (CI) = (0.995 – 1.777, p = 0.054)), recurrence-free survival (HR = 1.399, 95% CI = (1.106 – 1.770), p = 0.005) and overall survival (HR = 1.385, 95% CI = (1.046 – 1.834), = 0.023) but not for breast cancer specific survival (HR = 1.015, 95% CI = (0.684 – 1.505), p = 0.942). Conclusions hPG80 levels measured at diagnosis were significantly associated with the risk of recurrence or death from any cause in women with breast cancer. Since the recurrence rates of breast cancer are still relatively high amongst women diagnosed at an early stage, identifying women at high risk of recurrence at their time of diagnosis is important. hPG80 is a promising new prognostic biomarker that could improve the identification of women at higher risk of poor outcomes.

show abstract

Circulating proteins as predictive and prognostic biomarkers in breast cancer

Cited by 37 publications

References 153 publications

Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review

Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review

Potential Early Markers for Breast Cancer: A Proteomic Approach Comparing Saliva and Serum Samples in a Pilot Study

Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort

Contact Info

Product

Resources

About